- Home
- CINT vs ARVN Comparison
CINT vs ARVN Comparison
Compare CINT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- ARVN
- Stock Information
- Founded
- CINT 1995
- ARVN 2015
- Country
- CINT Brazil
- ARVN United States
- Employees
- CINT N/A
- ARVN 430
- Industry
- CINT EDP Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- ARVN Health Care
- Exchange
- CINT Nasdaq
- ARVN Nasdaq
- Market Cap
- CINT 670.2M
- ARVN 676.2M
- IPO Year
- CINT 2021
- ARVN 2018
- Fundamental
- Price
- CINT $5.08
- ARVN $9.45
- Analyst Decision
- CINT Strong Buy
- ARVN Buy
- Analyst Count
- CINT 5
- ARVN 23
- Target Price
- CINT $7.36
- ARVN $17.61
- AVG Volume (30 Days)
- CINT 285.5K
- ARVN 2.6M
- Earning Date
- CINT 11-13-2025
- ARVN 11-04-2025
- Dividend Yield
- CINT N/A
- ARVN N/A
- EPS Growth
- CINT 34.66
- ARVN N/A
- EPS
- CINT 0.25
- ARVN N/A
- Revenue
- CINT $452,826,000.00
- ARVN $372,800,000.00
- Revenue This Year
- CINT $12.57
- ARVN $1.01
- Revenue Next Year
- CINT $12.91
- ARVN N/A
- P/E Ratio
- CINT $20.22
- ARVN N/A
- Revenue Growth
- CINT 1.02
- ARVN 299.57
- 52 Week Low
- CINT $3.98
- ARVN $5.90
- 52 Week High
- CINT $8.00
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- CINT 59.24
- ARVN 57.54
- Support Level
- CINT $4.13
- ARVN $9.01
- Resistance Level
- CINT $5.17
- ARVN $9.55
- Average True Range (ATR)
- CINT 0.23
- ARVN 0.49
- MACD
- CINT 0.11
- ARVN -0.10
- Stochastic Oscillator
- CINT 92.56
- ARVN 44.37
About CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.